What is Retatrutide?

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A single-molecule triple agonist (GLP-1, GIP and glucagon receptors). Framed as a metabolic and mitochondrial reprogramming peptide where weight loss is a side effect. Ranked above semaglutide and tirzepatide, which are said to lose far more lean mass and ignore the glucagon axis. Oral GLP-1 drugs are dismissed.

Mechanism (as described)

• GLP-1 arm: satiety signal to the hypothalamus, slower gastric emptying, insulin release only when glucose is high.
• GIP arm: amplifies insulin sensitivity and favors healthy fat-cell storage over inflamed visceral fat.
• Glucagon arm: the "energy liberation" signal.
• Drives lipolysis and liver fat clearance, addressing hepatic insulin resistance.
• Raises energy expenditure (~20–25% cited).
• Keeps thyroid and sympathetic tone up in a deficit.
• With GLP-1/GIP present, it's steered toward thermogenesis rather than higher glucose.
• Brain: crosses the blood-brain barrier and resets the hypothalamic set point (leptin sensitivity), which is presented as why weight stays off. Restores central insulin sensitivity, lowers tau phosphorylation and neuroinflammation.
• Other effects:
• Raises PGC-1α and AMPK.
• Supports muscle protein synthesis.
• Lowers fasting insulin, HOMA-IR, TNF-α/IL-6 and NLRP3.
• Removes pancreatic fat (beta-cell recovery).
• Improves lipids and HbA1c (average ~5.2% cited).
• GLP-1 receptors on immune cells also let it modulate immunity.

Additional points (as described)

• Why it differs from semaglutide/tirzepatide: those mostly cut appetite, and cited as ~50% (up to ~70% without lifting) of their weight loss as lean tissue, leaving less muscle to absorb glucose. Retatrutide's glucagon arm frees fat (especially visceral), burns liver fat (clearing DAG/ceramides), lowers liver CRP and NLRP3, and raises energy use while sparing muscle.
• The GIP arm favors new small, healthy fat cells over enlarged inflamed ones, and steers any storage to under the skin rather than around organs. Insulin release is glucose-dependent, so lows are avoided.
• Long action comes from a fatty-acid side chain riding on albumin (a slow-release reservoir). That's why microdosing creates peaks, troughs and receptor fatigue.
• Brain: framed as improving brain insulin handling, insulin-degrading-enzyme function and neuronal fuel use. Mood is tied to the same inflammation, brain insulin resistance and ATP problems.
• Stopping: gains (mitochondria, insulin sensitivity) are said to mostly persist if habits hold; regain comes from old habits.
• Psychological or compulsive overeating may respond better to tesofensine.
• Pre-reconstituted products and blends are rejected.